Januvia (sitagliptin) is generally well tolerated, with the most common side effects being mild: stuffy or runny nose, upper respiratory infections, and headaches. These affect roughly 5 to 6% of people taking the medication. However, there are several rare but serious reactions worth knowing about, including pancreatitis, severe joint pain, and a blistering skin condition.
How Januvia Works
Januvia belongs to a class of diabetes drugs called DPP-4 inhibitors. Your gut naturally releases a hormone that tells your pancreas to produce insulin after you eat. The problem is that an enzyme (DPP-4) breaks down this hormone almost immediately. Januvia blocks that enzyme, letting the hormone stick around longer. The result: your pancreas releases more insulin when blood sugar is high, your liver produces less sugar, and your blood sugar levels come down. Because this system only kicks in when blood sugar is elevated, Januvia carries a low risk of pushing your blood sugar too low on its own.
Common Side Effects
In clinical trials reported in the FDA prescribing label, the side effects that showed up in at least 5% of patients (and more often than placebo) were relatively minor. Nasopharyngitis, the medical term for a common cold or sore throat, occurred in about 5.2% of people on Januvia alone compared to 3.3% on placebo. Upper respiratory tract infections appeared at similar rates, around 5 to 6%. Headaches affected about 5 to 6% of patients in various combination-therapy trials, compared to roughly 2 to 4% on placebo.
These numbers mean the difference between Januvia and a sugar pill is small for these common effects. Most people taking Januvia don’t notice any side effects at all, and those who do typically find them manageable.
Low Blood Sugar Risk
One of Januvia’s advantages is that it rarely causes hypoglycemia (low blood sugar) when used alone or paired with metformin. In real-world data, combining metformin with Januvia produced significantly fewer episodes of low blood sugar than combining metformin with a sulfonylurea, a different class of diabetes drug. The risk dropped by roughly 87% with the Januvia combination compared to the sulfonylurea combination.
That said, your risk changes if you take Januvia alongside insulin or a sulfonylurea. These medications already lower blood sugar aggressively, and adding Januvia on top can tip the balance. If you’re on one of these combinations, watch for the classic signs of low blood sugar: shakiness, sweating, confusion, and rapid heartbeat.
Pancreatitis
Acute pancreatitis is the most discussed serious risk with Januvia and other DPP-4 inhibitors. The UK’s medicines regulatory agency (MHRA) puts the reporting rate somewhere between 1 in 1,000 and 1 in 100 patients, though the precise frequency is uncertain because few cases appeared in clinical trials.
The hallmark symptom is persistent, severe abdominal pain that sometimes radiates to the back. This is not a mild stomachache. It’s intense and doesn’t go away. If you experience this kind of pain while taking Januvia, it needs immediate medical attention. Januvia is typically stopped permanently if pancreatitis is confirmed.
Severe Joint Pain
In August 2015, the FDA issued a safety warning about severe and disabling joint pain associated with DPP-4 inhibitors including Januvia. In most reported cases, symptoms started within a month of beginning the medication, but the timeline ranged widely, from a single day to years after starting treatment. The joint pain typically resolves after stopping the drug. This is considered rare, but worth being aware of if you develop new or worsening joint symptoms after starting Januvia.
Allergic and Skin Reactions
Serious allergic reactions, including swelling of the face, lips, tongue, or throat and difficulty breathing, have been reported with Januvia. These are rare but require emergency care.
A less well-known reaction is bullous pemphigoid, a skin condition that causes large, fluid-filled blisters. With DPP-4 inhibitors, these lesions typically appear months to years after starting the medication, making the connection easy to miss. The blisters are usually itchy and red, starting on the arms and legs before potentially spreading. Unlike some forms of this condition, the drug-related version tends to appear without much redness or hive-like irritation surrounding the blisters. It resolves after discontinuing the medication, though it may require treatment in the meantime.
Heart Health
Early concerns about DPP-4 inhibitors and heart failure prompted a large trial called TECOS, which followed over 14,000 people with type 2 diabetes and existing cardiovascular disease. The results were reassuring. The rate of major cardiovascular events (heart attack, stroke, cardiovascular death, or hospitalization for unstable chest pain) was 11.4% with Januvia versus 11.6% with placebo, showing no increased risk. Heart failure hospitalizations were identical at 3.1% in both groups. Even among people who already had heart failure at the start of the trial, rates were virtually the same: 7.4% with Januvia versus 7.0% with placebo.
This puts Januvia in the “cardiovascular neutral” category. It doesn’t appear to help the heart the way some newer diabetes drugs do, but it doesn’t harm it either.
Effect on Body Weight
Januvia is considered weight-neutral, meaning it generally doesn’t cause significant weight gain or weight loss. This sets it apart from sulfonylureas and insulin, which often lead to weight gain, and from GLP-1 receptor agonists (like semaglutide), which tend to promote weight loss. Some research has found that sitagliptin can modestly reduce BMI in people who gained weight on insulin therapy, but for most people, weight stays roughly stable. If weight management is a priority alongside blood sugar control, this is a useful factor to weigh when comparing treatment options.